(Corrects to say revenue fell, not rose, in paragraph 3)
April 26 (Reuters) - Vertex Pharmaceuticals Inc’s quarterly profit fell 15.1 percent, hurt by higher research and development spending.
Vertex said on Thursday income attributable to the company fell to $210.3 million or 81 cents per share in the three months ended March 31, from $247.8 million or 99 cents per share, a year earlier.
Vertex, one of the top U.S. manufacturers of treatments for lung disorder cystic fibrosis, said its revenue fell to $640.8 million from $714.7 million.
The company also separately said it had begun a late-stage study of a triple combination treatment for cystic fibrosis. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)